NASDAQ · NOTV
Healthcare · Medical - Diagnostics & Research
$0.08
Up+$0.04 (+121.94%)
Updated Aug 21, 2026, 11:30 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NOTV does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NOTV.
NOTV research
Company profile and research snapshot.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 10, 2026 | Lake Street | Buy | — |
| Dec 4, 2025 | Lake Street | Buy | — |
| May 8, 2025 | Lake Street | Buy | — |
| Sep 30, 2024 | Lake Street | Buy | — |
| May 16, 2024 | Craig-Hallum | Buy | — |
No generated briefing is available yet.
Benzinga · Feb 13, 2026
Inotiv is issuing this release for the limited number of individuals whose information was potentially involved but for whom Inotiv could not locate valid contact information.Inotiv recommends that individuals remain
SeekingAlpha · Feb 9, 2026
ChartMill · Feb 9, 2026
Inotiv's Q1 FY2026 results show a revenue miss and wider-than-expected loss, driving a sharp negative market reaction.
Benzinga · Feb 9, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NOTV.
